View printer-friendly version

<< Back

ImmunoGen, Inc. Announces Webcast of Panel Session at the RBC Capital Markets 2008 Healthcare Conference

WALTHAM, Mass., Dec 04, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Daniel Junius, President and Chief Operating Officer, will participate on the panel, The Power of Collaboration: Genentech and Its Partners, at the RBC Capital Markets 2008 Healthcare Conference. This 55-minute panel session will begin at 10:00 am EST on Thursday, December 11, 2008, and will be webcast live. The Conference will take place at the Westin New York at Times Square hotel in New York City. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and a naked antibody AVE1642 is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. ImmunoGen, Inc. Carol Hausner, 781-895-0600 Executive Director, Investor Relations and Corporate Communications info@immunogen.com